Biosensors & POCT– category –
-
Boston University Identifies Cardiovascular Metabolic Risk Patterns in Non-Diabetic Adults via CGM Data
EurekAlert! (Boston University Chobanian & Avedisian School of Medicine) USA Overview Researchers at Boston University have discovered that glucose patterns recorded by continuous glucose monitoring (CGM) devices in non-diabetic adults a... -
Precedence Research Outlines Digital Biomarker Market Growth Driven by Wearables and AI Healthcare
Precedence Research Unknown Overview Precedence Research has published an overview of its market research report, indicating significant growth in the digital biomarker market, primarily fueled by the increasing adoption of wearable devi... -
CAP Emphasizes Crucial Role of Rapid POCT in Combating STIs, Driving Efficient Care
The National Law Review USA Overview The College of American Pathologists (CAP) has published an article highlighting the significant benefits of point-of-care testing (POCT) for sexually transmitted infections (STIs), emphasizing its ro... -
DGIST-Led Team Develops Graphene Nanowall ‘Nanomesh’ Boosting Wearable Gas Sensor Sensitivity Sixfold, Achieving 2.4 ppm NO2 Detection
Graphene-Info South Korea Overview A research team including DGIST has developed a hierarchical graphene nanowall (GNW) 'nanomesh' that boosts wearable gas sensor sensitivity up to six times compared to conventional planar graphene senso... -
Abbott Receives FDA Authorization for Libre Duo 10 Day: World’s First Dual Continuous Glucose and Ketone Monitoring System for Early DKA Warning
Medical Update Online (Abbott) USA Overview Abbott has secured FDA authorization for its Libre Duo 10 Day, the world's first dual continuous glucose and ketone monitoring (CGKM) system. This novel bio-wearable provides real-time glucose ... -
Future of Continuous Glucose Monitoring: IDF Europe Advocates User-Centric Approach for Technology Selection in 2026
IDF Europe Belgium Overview IDF Europe has released an expert opinion asserting that Continuous Glucose Monitoring (CGM) has become an indispensable tool transforming diabetes management and supporting personalized care by 2026. Newer ge... -
Food Navigator Predicts Future of Gut Health: Multi-Analyte Biosensors and AI to Generate Real-Time Personalized Nutrition Recommendations
Food Navigator Ireland Overview Food Navigator forecasts that the future of gut health will be driven by the convergence of multi-analyte biosensors and AI, enabling real-time, highly personalized nutrition and health recommendations. Th... -
FDA Classifies Continuous Glucose Monitor Retrospective Data Analysis Software as Class I, 510(k) Exempt Medical Device
FDA.gov USA Overview The U.S. FDA has classified continuous glucose monitor retrospective data analysis software (Product Code PHV) as a Class I medical device, exempting it from 510(k) premarket notification. This software is intended t... -
FDA Approves Minor Firmware Design Changes for Dexcom G5 Mobile CGM System Transmitter Component
FDA.gov USA Overview The U.S. FDA has granted a Premarket Approval (PMA) supplement for minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring System. This approv... -
LMS and Impli Launch €6M International Challenge to Revolutionize Hormone Monitoring with BEAM Biosensor Platform for Simultaneous 5-Hormone Measurement
MRC Laboratory of Medical Sciences UK Overview MRC Laboratory of Medical Sciences (LMS) has partnered with technology company Impli in a €6 million international challenge to transform hormone monitoring. The program aims to extend Impli...
